A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Neoantigen DNA vaccine AstraZeneca/Washington University School of Medicine (Primary) ; Tremelimumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions
Acronyms PIVOT-RCC

12 Aug 2020 Status changed from not yet recruiting to withdrawn prior to enrolment as FDA Contingencies unresolved.
15 Jul 2020 Planned End Date changed from 31 Mar 2024 to 31 May 2024.
15 Jul 2020 Planned primary completion date changed from 31 Oct 2022 to 31 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com